Research programme: ROR gamma receptor modulators - Karo Pharma/Pfizer

Drug Profile

Research programme: ROR gamma receptor modulators - Karo Pharma/Pfizer

Latest Information Update: 21 Dec 2016

Price : $50

At a glance

  • Originator Karo Bio; Pfizer
  • Developer Karo Pharma AB; Pfizer
  • Class Small molecules
  • Mechanism of Action Nuclear receptor subfamily 1 group F member 3 modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Research Autoimmune disorders

Most Recent Events

  • 21 Dec 2016 Early research development is ongoing in Sweden (Karo Pharma pipeline, December 2016)
  • 16 Jul 2016 No recent reports of development identified for research development in Autoimmune-disorders in Sweden
  • 26 Jun 2013 Karo Bio and Pfizer extend their collaboration to discover and develop RORgamma modulators for autoimmune disorders
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top